Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
Frankfurt - Delayed Quote EUR

Hansa Biopharma AB (publ) (24H.F)

Compare
1.9900
-0.0220
(-1.09%)
At close: April 4 at 8:06:05 AM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 24H.F

Recent News: 24H.F

View More
Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients
PR Newswire 25 days ago
Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results

Hansa Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results
PR Newswire last month
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
PR Newswire 2 months ago
Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome

Hansa Biopharma announces positive full results from 15-HMedIdeS-09 Phase 2 study and comparative analysis of imlifidase in patients with Guillain-Barré Syndrome
PR Newswire 3 months ago
Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease

Hansa Biopharma Completes Enrolment in Global Pivotal Phase 3 Trial of imlifidase in Anti-Glomerular Basement Membrane Disease
PR Newswire 3 months ago
Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome

Genethon and Hansa Biopharma Announce Initiation of a Phase 2 Trial of imlifidase as a Pre-Treatment to GNT-0003 in Severe Crigler-Najjar Syndrome
Business Wire 3 months ago
Hansa Biopharma to Attend Truist Securities BioPharma Symposium

Hansa Biopharma to Attend Truist Securities BioPharma Symposium
PR Newswire 5 months ago
Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results

Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial Results
PR Newswire 5 months ago
Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial

Hansa Biopharma's HNSA-5487 Achieved Rapid and Highly Robust IgG Reduction by More Than 95% and Clear Redosing Potential in First-in-Human Trial
PR Newswire 5 months ago
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
PR Newswire 6 months ago
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis

Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
PR Newswire 7 months ago
View More

Related Tickers

FARON.HE Faron Pharmaceuticals Oy
2.4300
-2.61%
 
AURA Aura Biosciences, Inc.
5.43
-4.90%
 
TECX Tectonic Therapeutic, Inc.
15.62
-6.30%
 
QTTB Q32 Bio Inc.
1.6400
+2.50%
 
UNCY Unicycive Therapeutics, Inc.
0.5159
-12.56%
 
TSHA Taysha Gene Therapies, Inc.
1.2200
-3.17%
 
OCUL Ocular Therapeutix, Inc.
6.36
-9.21%
 
RCKT Rocket Pharmaceuticals, Inc.
5.12
-7.91%
 
ALNY Alnylam Pharmaceuticals, Inc.
235.74
-10.08%
 
EWTX Edgewise Therapeutics, Inc.
11.51
-15.24%